JCB, Volume 19, Number 1, 2013 Commentary Vol.19 No. 1 (2013) The other side of innovation Peter J. Pitts Government sponsored comparative effectiveness research is the first step towards allowing Uncle Sam to push a restrictive formulary on more and more Americans – with step one in t Commentary Vol.19 No. 1 (2013) Fixing a broken drug development process John Holland It costs about $1.2 billion to bring a single new drug to market in the U.S. today.[1] With a combination of high late-stage failure rates and the high cost of drug t Article Vol.19 No. 1 (2013) Biotechnology valuation and governance: Drug development and board of directors composition Chad Houston This paper examines the valuation of biotechnology firms and measure firm value relative to the firms’ drug development pipelines, alliances with other firms, and the varied compos Article Vol.19 No. 1 (2013) China’s heparin revisited: What went wrong and has anything changed? Clifford S Mintz China is the world’s largest producer of crude heparin. In 2007, tainted Chinese crude heparin made its way into the global finished heparin supply chain killing 149 persons in 11 Article Vol.19 No. 1 (2013) A snapshot of the successful bio-clusters around the world: Lessons for South African biotechnology Nirvana S. Pillay Development of clusters has been one of the critical factors in the success of many countries in the field of biotechnology. Most of the literature has been focused on the biotechnology c Article Vol.19 No. 1 (2013) Use of medicines for carved out indications - Time for a change in approach? Brian Cordery All stake-holders in the pharmaceutical industry recognise that valuable new medicines can be obtained from investing in the research and development of new uses for existing drugs. The Article Vol.19 No. 1 (2013) Improving IPO market still not an exit path G. Steven Burrill Recent suggestions that improving IPO activity will lead biotech venture investors to lucrative exits seems to be a bit premature and detached from the reality of these deals. The maxim o Article Vol.19 No. 1 (2013) NPV modelling for the selection of value-creating biosimilar development candidates Klaus Nickisch The purpose of this study was to apply net present value (NPV) modelling to evaluate the financial attractiveness and business risk of different categories of biosimilars. Challenges and Legal and Regulatory Updates Vol.19 No. 1 (2013) EU Legal & Regulatory Update Ewan Grist